{"id":857923,"date":"2024-05-27T11:23:32","date_gmt":"2024-05-27T10:23:32","guid":{"rendered":"https:\/\/www.nosoinfo.be\/nosoinfos\/?p=857923"},"modified":"2024-05-27T11:23:32","modified_gmt":"2024-05-27T10:23:32","slug":"surveillance-of-bloodstream-infections-in-belgian-hospitals","status":"publish","type":"post","link":"https:\/\/www.nosoinfo.be\/nosoinfos\/surveillance-of-bloodstream-infections-in-belgian-hospitals\/?lang=nl","title":{"rendered":"Surveillance of bloodstream infections in Belgian Hospitals"},"content":{"rendered":"

Sciensano – Rapport 2023. (2022)\u00a0<\/span><\/h2>\n

\u00a0<\/p>\n

Introduction\u00a0<\/span><\/b><\/h3>\n

Hospital-associated bloodstream infections (HABSI) cause considerable morbidity and mortality and have an important potential for prevention, especially for those HABSI associated with invasive devices (1\u20135). In Belgium, a national hospital-wide surveillance system for HABSI exists since 1992 (6).\u00a0<\/span><\/p>\n

The objective of the surveillance programme on HABSI in Belgian hospitals is to enhance the quality of care provided at the hospital by:\u00a0<\/span><\/p>\n

\u2022 monitoring HABSI trends, with a focus on BSI that can be prevented, at hospital and national level with the objective to enhance and evaluate preventive measures,\u00a0<\/span><\/p>\n

\u2022 monitoring causal microorganisms and their resistance profile.\u00a0<\/span><\/p>\n

The surveillance programme on HABSI in Belgian hospitals provides a standardized tool to (1) allow hospitals to follow-up their own HABSI and associated antimicrobial resistance trends at hospital and intensive care unit (ICU) level, and to (2) analyse data at national level.\u00a0<\/span><\/p>\n

Participation in the surveillance for a minimum of one quarter a year is legally required since 1 July 20142.The surveillance protocol has been reviewed and considerably updated and changed in 2013. This updated protocol aimed to focus on the usefulness of the surveillance as a tool for prevention of HABSI at hospital level.\u00a0<\/span><\/p>\n

This report describes trends in incidences of HABSI, causal microorganisms (MO), and their antimicrobial resistance profile until 2022 and provides a more detailed description of the 2022 BSI data. The descriptive report describes the results of a selection of main indicators for this surveillance. The statistical report includes exhaustive indicators, while the annexes show results on additional indicators including those stratified by region and hospital type..<\/p>\n

Om meer erover te weten: <\/b>https:\/\/www.sciensano.be\/en\/projects\/national-surveillance-bloodstream-infections-belgian-hospitals<\/a><\/p>\n

\u00a0<\/p>\n

\t
<\/form> \t
\t\tDownload article as PDF<\/a> \t<\/div> <\/div>","protected":false},"excerpt":{"rendered":"

Sciensano – Rapport 2023. (2022)\u00a0 \u00a0 Introduction\u00a0 Hospital-associated bloodstream infections (HABSI) cause considerable morbidity and mortality and have an important potential for prevention, especially for those HABSI associated with invasive devices (1\u20135). In Belgium, a national hospital-wide surveillance system for HABSI exists since 1992 (6).\u00a0 The objective of the surveillance programme on HABSI in Belgian […]<\/p>\n","protected":false},"author":2,"featured_media":4780,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[],"tags":[],"class_list":["post-857923","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t